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Due to increased sensitivity the expression of circulating nucleotides is rapidly gaining popularity in 39 
cancer diagnosis. Whole blood mRNA has been used in studies on a number of cancers, most notably 40 
two separate studies that used whole blood mRNA to define non-overlapping signatures of prostate 41 
cancer that has become castration independent. Prostate cancer is known to rely on androgens for 42 
initial growth and there is increasing evidence of the importance of the androgen axis in advanced 43 
disease. Using whole blood mRNA samples from patients with prostate cancer we have identified the 44 
4-gene panel of FAM129A, MME, KRT7 and SOD2 in circulating mRNA that are differentially 45 
expressed in a discovery cohort of metastatic samples. Validation of these genes at the mRNA and 46 
protein level was undertaken in additional cohorts defined by risk of relapse following surgery and 47 
hormone status. All four genes were down-regulated at the mRNA level in the circulation and in 48 
primary tissue but this was not always reflected in tissue protein expression. MME demonstrated 49 
significant differences in the hormone cohorts while FAM129A is down-regulated at the mRNA level 50 
but is raised at the protein level in tumours. Using published chIP-seq data we have demonstrated that 51 
this may be due to AR binding at the FAM129A and MME loci in multiple cell lines. These data 52 
suggest that whole blood mRNA of androgen regulated genes has the potential to be used for 53 
diagnosis and monitoring of prostate cancer. 54 
 55 




Prostate cancer is the leading cause of cancer death in men (Statistics 2013). Prostate cancer growth 58 
relies upon androgens, such as testosterone, binding to the androgen receptor (AR) and promoting AR 59 
binding to DNA via androgen response elements where it regulates the transcription of androgen 60 
regulated genes (Claessens, et al. 2014). Due to the importance of the AR signalling axis, treatment 61 
for prostate cancer relies upon blocking the production of androgens or their binding the AR. 62 
Although this treatment is effective, patients will eventually relapse as prostate cancer cells continue 63 
to grow, despite continued hormone therapy. This stage of disease was originally termed hormone 64 
independent or refractory but recent evidence, including the use of drugs to block adrenal androgen 65 
synthesis (abiraterone) or binding to the AR (enzalutamide), suggests that the AR axis remains active 66 
in advanced prostate cancer and is a valid therapeutic target (Mateo, et al. 2014). This is supported by 67 
the critical involvement of androgen regulated genes to predict aggressive prostate cancer in a 68 
recently published gene signature found in tissue (Klein, et al. 2014).     69 
 70 
Diagnostic prostate cancer biomarkers primarily detect differences between benign prostates and 71 
those containing primary tumour. Despite the large number of published manuscripts describing 72 
biomarkers for detecting prostate cancer, the detection of androgen regulated prostate specific antigen 73 
(PSA) in serum remains the primary biochemical test used for diagnosis (Egger, et al. 2013; Kattan, et 74 
al. 1998; Partin, et al. 1993). PSA is not an ideal prostate cancer biomarker as it can be elevated by a 75 
number of benign conditions including benign prostatic hyperplasia and prostatitis. PSA has a 76 
sensitivity of approximately 80% but specificity as low as 20% resulting in false positive and negative 77 
results (Catalona, et al. 1994; Thompson, et al. 2005). PCA3, a small non-coding RNA that can be 78 
detected in urine, is increasingly being used for prostate cancer diagnosis, particularly in patients with 79 
raised PSA and at least one negative biopsy (de Kok, et al. 2002; Haese, et al. 2008). This is despite 80 
the requirement for prostatic massage and reports of relatively poor sensitivity (65%) and specificity 81 
(60%) (Hessels and Schalken 2009). Unlike PCA3, PSA has shown some promise in predicting 82 
aggressive disease and relapse following treatment but this remains an area of prostate research where 83 
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novel markers could significantly impact on clinical decisions (Augustin, et al. 2013; Botchorishvili, 84 
et al. 2009). 85 
 86 
Over 30 years ago, Leon et al. showed that circulating DNA levels were increased in cancer patients 87 
compared to healthy controls (Leon, et al. 1977). Circulating nucleic acids as biomarkers have 88 
advantages over proteins such as the ability to be amplified and detected with high sensitivity and 89 
specificity. Expression arrays and real-time quantitative PCR (qPCR) allow quantification of many 90 
genes in a single experiment. (Schwarzenbach, et al. 2011). More recently whole blood mRNA has 91 
been investigated for the discovery and development of biomarkers as RNA is more labile and may 92 
more accurately reflect any early changes in cells leading to tumour development (Miura, et al. 2005; 93 
Papadopoulou, et al. 2006; Williams 2010). The PAXgene system is used for the storage and 94 
purification of RNA from blood and provides storage of blood samples for 50 months at -20oC 95 
(Rainen, et al. 2002). Its use has enabled the investigation of differences between whole blood mRNA 96 
expression levels in patient samples with haematological and rheumatological diseases, breast, thyroid 97 
and prostate cancers (Batliwalla, et al. 2005; Lewis, et al. 2011; Li, et al. 2004; Yang, et al. 2011). 98 
In prostate cancer there have been a number of recent publications utilising PAXgene samples for 99 
prognosis to identify those primary prostate cancers that are likely to be life limiting (indolent primary 100 
versus aggressive disease) (Danila, et al. 2013; Liong, et al. 2012; Marin-Aguilera, et al. 2015; Olmos, 101 
et al. 2012; Ross, et al. 2012). In back-to-back publications Olmos et al. and Ross et al. showed different 102 
gene signatures, both capable of predicting shortened survival in patients with castration-resistant 103 
prostate cancer (Olmos et al. 2012; Ross et al. 2012). Using genes pre-selected by literature review Ross 104 
et al. used unamplified whole blood mRNA to define a six-gene model which separated castrate-105 
resistant patients into a low risk group with median survival of 34.9 months compared to a high risk 106 
group with a median survival of 7.8 months (Ross et al. 2012). Using amplified whole blood mRNA 107 
Olmos et al. used Affymetrix expression arrays and Bayesian latent process decomposition to identify 108 
a signature which divided their cohort into 4 groups with survival ranging from 9.2 months to 25.6 109 
months (Olmos et al. 2012). That these two manuscripts showed no overlap between the genes in their 110 
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signature for castration-resistant disease may reflect the use of candidate genes and RNA amplification 111 
which is known to introduce bias in expression arrays in the Olmos, but not the Ross, manuscript 112 
(Kitchen, et al. 2011). Other groups have used RNA from urine or the peripheral circulation to study 113 
previously identified and well characterised markers for prostate cancer using PCR-based methods and 114 
found they were robust, particularly when used in conjunction with circulating tumour cells (Danila et 115 
al. 2013; Quek, et al. 2012).   116 
Here we describe the identification of a whole blood mRNA gene signature from unamplified PAXgene 117 
samples using Illumina HT-12 expression arrays. Genes were identified using the extremes of prostate 118 
pathology; a metastatic and benign discovery cohort. Differentially expressed genes were further 119 
validated in additional primary cohorts with defined hormonal status or risk stratification. In addition 120 
the gene panel was investigated at both the gene and protein level in the circulation and primary prostate 121 
tissue and AR binding to the gene locus determined.  122 
 123 
Materials and methods 124 
Unless otherwise stated all reagents were purchased from Sigma Aldrich (St. Louis, USA). 125 
Study design 126 
An overview of the study design is given in Figure 1A. All PAXgene samples were taken from patients 127 
enrolled in the ProMPT trial at Addenbrookes Hospital, Cambridge (National Institute of Health and 128 
Research ID 5837) between 2010 and 2012. Informed consent was obtained from each patient after full 129 
explanation of the purpose and nature of all procedures used. 130 
 131 
The discovery cohort used PAXgene samples from 22 patients; 12 control patients with an elevated 132 
PSA and negative TRUS biopsy (benign), and 10 patients with metastatic prostate cancer. These 133 
patients also had core biopsy specimens taken from the primary prostate available for 134 
immunohistochemistry. An additional 10 samples from men with raised PSA who had undergone 135 
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template biopsy were analysed for comparison with the benign control group. The clinical 136 
characteristics are given in Table 1.  137 
The gene signature was validated in 2 cohorts; a defined hormone status cohort and a defined risk 138 
cohort. Hormone status was determined as those patients not receiving any hormone treatment 139 
(hormone naïve), patients receiving hormone treatment and responding (stable disease) or patients no 140 
longer responding to hormone therapy (hormone refractory). For the risk cohort patients were defined 141 
as low, intermediate or high risk based on the following clinical criteria; low risk – PSA ≤10ng/ml, 142 
Gleason 6, ≥T2, intermediate risk – PSA ≥10ng/ml but ≤20ng/ml, Gleason 7, ≥T2 or high risk – PSA 143 
≥20ng/ml, Gleason ≥8, ≥T3. The clinical characteristics of the risk cohort are given in Table 2. For this 144 
study hormone refractory patients are defined as those with two consecutive PSA rises to ≥0.2ng/ml. 145 
The clinical characteristics are given in Table 3.  146 
 147 
RNA extraction and cDNA formation 148 
2.5ml of whole blood was taken from patients using PAXgene tubes (GenProbe, (San Diego, USA)) 149 
and stored according to the manufacturer’s instructions. RNA was extracted using the PAXgene RNA 150 
Blood kit (Qiagen, (Limburg, Netherlands)) and eluted in 80µL of elution buffer. RNA quantification 151 
was performed by absorbance (OD A260nm) on the Nanodrop ND1000 instrument (Thermo Scientific, 152 
(Cambridge, UK)). 500ng of RNA per sample was reverse transcribed to cDNA using High Capacity 153 
RNA-to-cDNA Master Mix (Applied Biosystems, (California, USA)). 154 
 155 
RNA Expression Array 156 
Using 22 samples in the discovery cohort (benign (n=12) and metastatic n=10)), gene expression 157 
analysis was carried out on Illumina Human HT12 version 4 arrays (Illumina, (San Diego, USA)). Data 158 
analyses were carried out on R using Bioconductor packages (Gentleman 2004). Raw intensity data 159 
from the array scanner was processed using the BASH and HULK algorithms as implemented in the 160 
beadarray package (Cairns 2008; Dunning 2007). Log2 transformation and quantile normalisation of 161 
the data was performed across all sample groups. Differential expression analysis was carried out using 162 
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the limma package (Smyth 2005). Genes were selected for further analysis by ranking according to an 163 
unadjusted p-value and a cut off of 0.01 applied to stratify genes more likely to be significantly altered. 164 
Following interrogation of the top ranked genes data was ranked by p-value and then fold change. 165 
Further stratification of genes was completed using published datasets to identify differentially 166 
expressed genes associated with poor prognosis(Glinsky, et al. 2004; Taylor, et al. 2010). Genes with 167 
published antibodies for immunohistochemistry or good differential expression between tumour and 168 
benign glands in Human Protein Atlas were preferentially selected. A table of how genes were selected 169 
and what criteria were taken into account is shown in Supplementary Table 2.  170 
 171 
A false discovery rate (FDR) of 0.39 was calculated for the top 100 probes indicating that only 61/100 172 
were likely to be true positives and that additional validation was required to confirm any candidate 173 
genes.  174 
 175 
Quantitative Real-Time Polymerase Chain Reaction 176 
Quantitative real-time Polymerase Chain Reaction (qPCR) was performed in triplicate using 2pmol 177 
Sigma primers, 5µl of SYBR Green and 10ng of cDNA template using the Applied Biosystems 7900HT 178 
Real-Time PCR system. Primer sequences are given in Supplementary Table 3. Ct values were 179 
calculated and the expression of target genes was normalised against the expression of RPLP2 180 
housekeeping gene using the δδCt method. RPLP2 was chosen as a housekeeping gene by analysing all 181 
genes in the expression array with high expression and minimal variation (Supplementary Figure 1).  182 
 183 
Chromatin Immunoprecipitation: 184 
Chromatin was immunoprecipitated  from LNCaP cells treated with either  1nM R1881 or vehicle 185 
(ethanol) for 1hour as described in Massie et al.(Massie and Mills 2009) using 10µg AR n-20 186 
antibody (sc-816, Santa Cruz Biotechnology) and an equal mixture of Dynabeads Protein A and G 187 
(10001D and 10003D, Life Technologies). Primer sequences are shown in Supplementary Table 4. 188 






For immunohistochemistry tissue cores taken from the primary prostate of patients within the discovery 193 
cohort were used. In addition a TMA was constructed from multiple benign and tumour samples from 194 
104 patients who underwent radical prostatectomy as previously described (Whitaker, et al. 2010; 195 
Whitaker, et al. 2013). Immunohistochemistry was also performed on a hormone relapsed TMA 196 
comprised of 74 patients, of which 9 were on hormone treatment and responding and 50 initially 197 
responded to treatment but subsequently underwent biochemical or clinical relapse as described 198 
(Ramos-Montoya, et al. 2014). The clinical characteristics are given in Table 4.  199 
 200 
All immunohistochemistry was performed using a Bondmax Autostainer (Leica (Solms, Germany)) 201 
using the following antibodies; FAM129A (1:750, Atlas Antibodies (Stockholm, Sweden)), KRT7 202 
(2.8g/L, Novocastra (Solms, Germany)), SOD2 (1:1500, Atlas Antibodies) and MME (1:50, 203 
Novocastra). Citrate buffer pH6.0 (ER1) was used for all antigen retrieval. KRT7 has been validated 204 
and is sold for routine use in the clinical setting using the same conditions and Bondmax Autostainer 205 
(Addenbrookes Hospital). The specificity of antibody staining by FAM129A, SOD2 and MME was 206 
validated using qPCR and immunohistochemistry of formalin fixed paraffin embedded LNCaP cell 207 
pellets transiently transfected with siRNA against each target or a non-targeting control (Supplementary 208 
Figure 2). Loss of staining in the specific cellular compartment in up to 50% of cells in the siRNA group 209 
was considered specific. Confirmation of pathology was conducted by a uropathologist (AW) for all 210 
samples. All scoring was done independently by two observers (one an independent specialist uro-211 
oncology pathologist) who were both blinded to the TMA plan. Staining was classified into the 212 
following categories: none (-), weak (+), moderate (++) and high (+++), based on intensity. For the 213 
TMA, where multiple pathologies were present in a single core, each was scored independently and 214 
multiple scores given for distinct grades of cancer. For core biopsies where cancer was present, it was 215 





All assays were performed on the MesoScale Discovery (MSD) platform (Maryland USA). Normal 219 
bind plates were coated at 4°C overnight with 30µl goat anti-MME antibody (1.44µg/ml, R&D 220 
Systems) before washing and blocking with MSD blocker A. After diluting 1:5 in Delfia diluent II 221 
(Perkin Elmer (Massachusetts, USA)), 50µl of serum sample or standard was added to each well and 222 
incubated for 2 hours at room temperature. After washing, 25µl of biotinylated goat anti-MME 223 
antibody (1:100, R&D Systems (Minneapolis, USA)) was added per well and incubated at room 224 
temperature for 1 hour. Signal was detected using streptavidin sulphoTAG (1:1000, MSD) incubated 225 
for 30 mins at room temperature. Wells were washed and 150µl MSD read buffer added prior to 226 
detection on a Sector 6000 plate reader. Standards ranging from 39-40,000pg/ml were made using 227 
recombinant MME (R&D Systems) and Delfia diluent II. A standard curve was run alongside all 228 
samples to ensure reproducibility of the assay. 229 
 230 
Androgen regulation of LNCaP cells and AR chIP-seq 231 
Gene expression data were generated as part of a previously published study (Massie, et al. 2011). 232 
Briefly, LNCaP cells grown for 72 h in steroid depleted medium prior to treatment with the synthetic 233 
androgen R1881. Samples included 3 time zero samples; 10 vehicle (ethanol) control samples taken at 234 
2, 4, 8, 12 and 24 h in duplicate and 36 androgen (R1881)-treated samples taken every 30 min for 4 h 235 
then every hour until 24 h following treatment (with replicates at 1, 2, 4, 8, 12, 16, 20 and 24 h). Gene 236 
expression data was analysed as before (Massie et al. 2011). The AR chIP-seq experiments have 237 
previously been described (Massie et al. 2011; Wang, et al. 2009; Yu, et al. 2010). 238 
 239 
Data analysis and modelling 240 
Grouped p-values were calculated using a Kruskal-Wallis test. Pairwise analysis was performed using 241 
a Mann-Whitney two-tailed t-test. For both analysis a p-value of <0.05 was considered to be statistically 242 
significant. Previously published expression array data from prostate tissue was analysed using 243 
recursive partitioning to predict time to biochemical recurrence from 179 patients (29 benign, 131 244 
localised prostate cancer and 19 metastatic disease) (Taylor et al. 2010). Recursive partitioning was also 245 
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used to determine qPCR cut-offs between groups in the defined hormone status cohort and the defined 246 
risk cohort using the ctree function in R (Hothorn 2006). Models were fitted for all 4 genes and serum 247 
PSA individually. 248 
 249 
Results 250 
Identification of genes capable of discriminating between benign and metastatic patients 251 
To discover if any genes demonstrated significant differential expression between benign and tumour 252 
cohorts a discovery cohort were selected which represented the extremes of prostate disease; 10 253 
metastatic and 12 benign samples. To ensure that there were no fundamental differences between the 254 
blood samples from each group baseline haematological parameters such as haemoglobin and white 255 
blood cells were assessed and were not significantly different (Supplementary Figure 3).  256 
 257 
The mRNA from the discovery cohort samples were assessed using Illumina Human HT12 v4 258 
expression arrays with and without haemoglobin reduction, which has been reported to influence 259 
measurement of accurate expression using gene arrays (Fan and Hegde 2005; Vartanian, et al. 2009). 260 
Although the signal to noise ratio was much lower in the haemoglobin reduced samples, when 261 
candidate genes were validated by qPCR using the original PAXgene samples without haemoglobin 262 
reduction, they were not significant suggesting that haemoglobin mRNA reduction had altered the 263 
samples significantly (Supplementary Figure1A and data not shown). The 100 top differentially 264 
expressed genes in the non-haemoglobin reduced samples are shown in Supplementary Figure 4. Six 265 
genes were taken forward for further analysis; family with sequence similarity 129, member A 266 
(FAM129A) also known as NIBAN, pyrophosphatase (inorganic) 1 (PPA1), dolichyl-phosphate 267 
mannosyltransferase polypeptide 3 (DPM3), superoxide dismutase-2 (SOD2), keratin-7 (KRT7) 268 
and membrane metallo-endopeptidase (MME) also known as CD10. Although unrelated, all of these 269 
genes have been previously associated with cancer and DPM3, SOD2, KRT7 and MME have 270 
previously been linked to prostate cancer (Supplementary Table 1). The genes identified in previous 271 
PAXgene studies failed to cluster our discovery cohort into benign and metastatic samples, probably 272 
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as a result of different sample processing methods (data not shown) (Olmos et al. 2012; Ross et al. 273 
2012).  274 
 275 
Figure 1B shows a heatmap of microarray data of probes for the six genes that were amongst the top 276 
1000 most differentially expressed probes. Boxplots of these probes are shown in Figure 1C for the 277 
benign and metastatic groups, along with the p-values from limma tests for differential expression 278 
between the groups. Further validation of these results using qPCR of fresh cDNA from same patients 279 
showed that three genes, KRT7, DPM3 and PPA1, were not significantly different between benign and 280 
metastatic groups despite DPM3 previously being linked to prostate cancer cell invasion (Figure 1D) 281 
(Manos, et al. 2001). This result was not unexpected given  the high FDR seen in the array probably 282 
due to the wide clinical parameters in the discovery cohort, non-specific binding to probes on the 283 
expression array or the increased sensitivity of qPCR. As KRT7 is routinely used as a basal cell marker 284 
in prostate cancer we took the decision to allow it to remain in the selected gene panel (Supplementary 285 
Table 1) (Ashida, et al. 2006; Manos et al. 2001). The remaining 3 genes FAM129A, SOD2 and MME 286 
all achieved statistical significance (p<0.05). The benign group within the discovery cohort all had 287 
raised PSA and at least one negative TRUS biopsy and therefore it was possible that up to 30% may go 288 
on to have a later diagnosis of prostate cancer (Shariat and Roehrborn 2008). To establish that this 289 
benign cohort was a valid control group qPCR for FAM129A, SOD2, MME and KRT7 was compared 290 
between the TRUS confirmed benign group and a cohort of benign prostates confirmed by template 291 
biopsy with a much lower probability of having cancer (<10%). This showed no significant differences 292 
and confirmed the benign group as a valid control (Supplementary Figure 5). 293 
 294 
Circulating mRNA may reflect gene expression and protein levels in tumour tissue  295 
It is hypothesised that the mRNA collected in PAXgene samples could be influenced by expression of 296 
specific genes in primary tumour tissue or be altered due to the immune response (Marin-Aguilera et 297 
al. 2015; Olmos et al. 2012; Ross et al. 2012). As no tissue RNA was available from our discovery 298 
cohort we examined gene expression of the four genes identified in a published independent cohort 299 
(Taylor et al. 2010). Expression of all four genes, FAM129A, SOD2, KRT7 and MME was 300 
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significantly reduced in metastatic samples when compared to benign, consistent with the results we 301 
found in circulating mRNA (Figure 2A). To establish if changes in circulating mRNA gene 302 
expression and tissue mRNA expression accurately reflected protein expression in the tumour the 303 
diagnostic biopsies from the benign prostates or primary tumours of the discovery cohort were 304 
examined using immunohistochemistry (IHC) for FAM129A, SOD2, MME and KRT7 (Figure 2B). 305 
FAM129A showed cytoplasmic staining and expression was reduced, albeit not significantly (p=0.17) 306 
in metastatic biopsy tissue when compared to benign. SOD2 showed ubiquitous punctate staining, 307 
consistent with its known mitochondrial localisation (Wispe, et al. 1989). In contrast to the mRNA 308 
expression and published data, protein levels increased in metastatic samples compared to benign, 309 
although not significantly (p=0.070) (Bostwick, et al. 2000). Both KRT7 and MME appeared to be 310 
associated with the plasma membrane, consistent with previous publications (Glass and Fuchs 1988; 311 
Zheng, et al. 2010). Protein expression of both decreased significantly with the metastatic group 312 
consistent with the whole blood mRNA (Figure 1). However, detection of MME protein in serum was 313 
not consistently reduced when measured by ELISA using samples from the same patients (Figure 2C). 314 
 315 
Localised disease stratified by risk 316 
Patients with localised prostate cancer that may be destined for surgery can be stratified into risk 317 
groups for relapse using a number of criteria include PSA, stage and grade (D'Amico, et al. 1999) 318 
Using recursive partitioning of the risk cohort serum PSA could distinguish low and high groups with 319 
a ≥11.3ng/ml cut off. We stratified 47 patients into low, intermediate and high risk groups as defined 320 
in the materials and methods, and tested their whole blood mRNA levels of FAM129A, KRT7, SOD2 321 
and MME (Figure 3A). Only circulating KRT7 and MME mRNA demonstrated any significant ability 322 
to discriminate between the risk groups. KRT7 was able to discriminate between low and intermediate 323 
risk groups (p=0.0061) and this was confirmed using recursive partitioning where nodes represent the 324 
point at which the most significant differences between the two arms exist (cut off ≥0.00042) (Figure 325 
3B). Overall PSA >11.3ng/ml performs better than KRT7 but with a PSA ≤11.3ng/ml they 326 
perform similarly. KRT7 and MME could both differentiate between intermediate and high risk 327 
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groups (p=0.0019 and p=0.011 respectively). This result was consistent with significant decreases in 328 
tissue expression of KRT7 and MME in localised prostate cancer from previously published data 329 
(Figure 3C, p<0.0001 and p=0.013 respectively) (Taylor et al. 2010). In the same dataset FAM129A 330 
exhibited no change between benign and localised tissue groups while SOD2 expression was raised 331 
controls (p=0.018) consistent with our findings at the protein level in the primary tissue biopsies 332 
(Figure 2B). Low expression of FAM129A, SOD2 and MME mRNA were able to predict poor 333 
prognosis in Taylor et al. with multiple probes (Taylor et al. 2010) while low tissue mRNA expression 334 
of FAM129A, KRT7 and SOD2 was also linked to poor outcome in data published by Glinsky et al. 335 
(Supplementary Figure 6) (Glinsky et al. 2004). 336 
 337 
To establish if changes in tissue mRNA and circulating mRNA in our PAXgene samples reflected 338 
protein expression in primary prostate tissue IHC was performed using an in-house Cambridge TMA 339 
for FAM129A, KRT7, SOD2 and MME protein (Figure 3D). All four proteins showed a significant 340 
difference between the benign and Gleason groups (p<0.0001). In contrast to circulating mRNA 341 
expression and primary tissue biopsies from metastatic patients, protein levels of FAM129A showed a 342 
significant increase in localised tumours compared to benign tissue. KRT7, SOD2 and MME all 343 
exhibited a decrease in protein expression when compared to benign tissue. This decrease was 344 
particularly striking for KRT7 and MME. 345 
 346 
Androgen regulation of the 4-gene panel  347 
Within the discovery cohort the metastatic patients were receiving a range of treatments which may 348 
have influenced the circulating mRNA levels of different genes. We used a well-defined hormone 349 
sensitivity cohort to determine the effect of hormone treatments on the circulating mRNA levels of the 350 
4-gene panel of FAM129A, SOD2, KRT7 and MME (clinical data is given in Table 3). These patients 351 
had either never received hormone treatment (hormone naïve), were receiving hormone treatment and 352 
responding (hormonal therapy) or were no longer responding to hormone therapy (hormone relapsed). 353 
Using a Kruskal Wallis test, detection of the mRNA coding for all 4 genes was significantly different 354 
between all groups for each gene (p<0.05) (Figure 4A). Circulating expression of mRNA coding for 355 
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FAM129A, SOD2 and MME showed a significant reduction in those patients responding to hormones 356 
compared to those receiving no treatment which may indicate androgen regulation of those genes. To 357 
determine cut-off points associated with hormone status recursive partitioning of the qPCR data was 358 
performed (Figure 4B). This was consistent with recursive partitioning of FAM129A, SOD2 and MME 359 
demonstrating that the hormone naïve (HN) group could be distinguished from the hormone treated 360 
groups (cut-offs >0.337 (FAM129A), 1.162 (SOD2) and 0.054 (MME)). None of the four genes were 361 
able to distinguish hormone relapsed patients from those responding to treatment using a Mann 362 
Whitney test, however even in the small numbers of patients in these cohorts recursive partitioning of 363 
the data for MME showed some ability to distinguish patients on hormonal therapy (HT, node 2) from 364 
hormone relapsed (HR, nodes 4 and 5) (Figure 4A and 4B).  365 
 366 
To establish if these changes in circulating mRNA reflected protein expression in a defined hormone 367 
cohort we performed IHC for FAM129A, KRT7, SOD2 and MME on a hormone relapsed TMA 368 
comprised of patients who were responding to hormone treatment hormonal therapy (HT)) or relapsed 369 
following hormone treatment (hormone relapsed (HR)) (Table 4). These results were compared to the 370 
untreated hormone naïve patients used in the in-house Cambridge TMA (Figure 3D). KRT7, SOD2 371 
and MME, but not FAM129A all showed highly significant differences across the three groups. There 372 
were no statistically significant pairwise analyses for either FAM129A or KRT7 at the protein level. 373 
However, both SOD2 and MME showed significant differences at the protein level when patients 374 
were treated with hormone (hormone naïve vs on hormonal therapy) (p<0.0001 (SOD2) and p=0.0028 375 
(MME))  376 
 377 
To determine if these observed changes in circulating mRNA and tissue protein were a result of 378 
androgen regulation of the 4-gene panel we examined data from an androgen time course of the 379 
LNCaP cell line which showed that only FAM129A expression was decreased following androgen 380 
treatment, consistent with our data (Figure 5A and Supplementary Figure 7). To determine if the AR 381 
binds to potential binding sites in the promoters of the 4-gene panel we examined published chIP-seq 382 
data from a variety of cell lines (Massie et al. 2011; Wang et al. 2009; Yu et al. 2010). These results 383 
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showed convincing AR binding in multiple prostate cancer cell lines for FAM129A and MME (Figure 384 
5B). There was evidence for AR binding at the KRT7 locus, but only in the two ERG positive VCaP 385 
cell line studies suggesting possible ERG involvement in KRT7 regulation (Massie et al. 2011; Yu et 386 
al. 2010) (Supplementary Figure 7). AR binding to the SOD2 locus was seen in two cell lines (LNCaP 387 
and VCaP) but only in data produced in our laboratory (Massie et al. 2011).  To confirm AR binding 388 
at the promoters of these genes chromatin immunoprecipiation (chIP) was performed in the LNCaP 389 
cell line using an anti-AR antibody (Figure 5C). Following 1 hour of treatment with the synthetic 390 
androgen, R1881, AR binding was significantly enriched at the FAM129A, KRT7 and MME 391 
promoters, but not the SOD2 promoter.  392 
 393 
Discussion 394 
The majority of diagnostic biomarkers are identified through studies comparing benign and primary 395 
prostate cancer. All previous studies using PAXgene samples to determine circulating mRNA 396 
signatures in prostate cancer have examined primary indolent versus aggressive prostate cancer either 397 
using pre-selected genes of interest or amplified the mRNA which is known to introduce bias (Danila 398 
et al. 2013; Kitchen et al. 2011; Marin-Aguilera et al. 2015; Olmos et al. 2012; Ross et al. 2012). In 399 
this study we have described the identification of genes initially using a benign versus metastatic 400 
comparison using Illumina Human HT12 v4 expression arrays without amplification or use of 401 
haemoglobin reduction which has been reported to improve data quality in PAXgene studies (Fan and 402 
Hegde 2005; Vartanian et al. 2009). Although we found that haemoglobin reduction did improve the 403 
data quality as defined by Illumina (Supplementary Figure 1), all subsequent qPCR validation in non-404 
haemoglobin reduced samples demonstrated that the mRNA in haemoglobin reduced samples did not 405 
accurately reflect the mRNA in the biological sample.  406 
Using expression arrays and native samples we compared the two extremes of prostate pathology in 407 
the discovery cohort comprising metastatic versus benign samples (Table 1) and identified 6 genes 408 
(FAM129A, PPA1, DPM3, SOD2, KRT7 and MME) for further study (Supplementary Table 1). Of 409 
these genes DPM3, SOD2, KRT7 and MME have all previously been linked to prostate cancer with 410 
DPM3 and MME also linked to aggressive disease although no common pathway links these genes 411 
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(Ho, et al. 2013; Manos et al. 2001; Voutsadakis, et al. 2012). KRT7 is widely used in cancer 412 
diagnosis as a marker for basal cells which are known to be lost in prostate cancer during neoplastic 413 
transformation (Brimo and Epstein 2012). Previous studies have suggested that loss of SOD2 414 
expression is an early event in tumour development, providing an environment for increased free 415 
radicals and the development of mutations (Hempel, et al. 2011). However, high levels of SOD2 have 416 
been reported in metastatic tissue and circulating prostate tumour cells where they are thought to 417 
enhance metastases (Giesing, et al. 2012; Hempel et al. 2011). MME protein is reduced in extra-418 
capsular versus organ confined prostate cancer and MMEhigh/AGR2low expression is more closely 419 
associated with primary disease whereas MMElow/AGR2high is more commonly seen in metastatic 420 
tissue (Ho et al. 2013; Kim, et al. 2012).  There have also been previous reports of FAM129A 421 
overexpression in renal and head and neck cancers where it has been shown to regulate cell stress and 422 
p53 degradation to promote cancer cell survival (Adachi, et al. 2004; Cerutti, et al. 2006; Ji, et al. 423 
2012; Matsumoto, et al. 2006; Patel, et al. 2011). We also reported a high FDR for our discovery 424 
cohort (0.39) indicating that although we were enriching for differentially expressed genes only 425 
61/100 were likely to be positive. We believe that this is most likely due to the wide range of clinical 426 
characteristics in the discovery cohort that had a range of hormone treatments and risk stages. 427 
Therefore further examination of any identified genes in well defined cohorts was essential.  428 
Four of these genes (FAM129A, KRT7, SOD2 and MME), were characterised in circulating mRNA, 429 
tissue mRNA and tissue protein levels in a defined hormone cohort and a risk stratified cohort based 430 
upon stage, Gleason grade and PSA data (D'Amico et al. 1999) (Figure 1D and Tables 2 and 3). The 431 
data generated in all of these cohorts is summarised in Table 5. All of the genes that we identified 432 
were down-regulated in prostate cancer which presents challenges in using them as practical 433 
biomarkers as technical assay issues can easily give rise to false positive results. The sensitivity of the 434 
methodology used for detection could limit the detection of aggressive forms of cancer and loss of 435 
signal due to epigenetic changes or mutations cannot always be ruled out. 436 
 437 
There was concordance in the expression of FAM129A, KRT7, SOD2 and MME in circulating mRNA 438 
and published metastatic tissue mRNA suggesting that circulating mRNA may accurately reflect 439 
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expression that occurs in metastatic tumour tissue either directly or via an immune response (Figures 440 
1C and 1D,  Figure 2A) (Taylor et al. 2010). This is consistent with the overexpression of a number of 441 
genes identified in circulating tumour cells derived from the tumour tissue (Marin-Aguilera et al. 442 
2015). In our study down-regulation of these four genes could also be confirmed at the protein level in 443 
primary tissue biopsies from metastatic men for KRT7 and MME but not SOD2 or FAM129A (Figure 444 
2B). This may reflect the small sample numbers tested or the effects of variable fixation on thin 445 
needle core biopsies. These results were supported by the down-regulation of KRT7, SOD2 and MME 446 
protein levels in localised tumours which suggests that these 3 genes, and subsequently proteins, are 447 
all down-regulated in all tumours compared to benign (Figure 3D and Table 5). Although FAM129A 448 
protein was down-regulated in biopsies from metastatic patients this result was not significant 449 
(p=0.17) and subsequent analysis in localised prostate cancer demonstrated a clear up-regulation in 450 
primary tumours (Figures 2B and 3D). For SOD2 the conflicting protein level data between primary 451 
biopsy of metastatic disease and localised disease is consistent with other conflicts in metastatic tissue 452 
and circulating tumour cells versus primary disease (Giesing et al. 2012; Hempel et al. 2011).  There 453 
were no significant changes in MME protein levels in both the discovery and defined risk cohorts, as 454 
well as in serum protein levels (Figures 1, 2C and 3). This may reflect the greater sensitivity 455 
frequently seen in genomic assays (Miura et al. 2005; Papadopoulou et al. 2006; Williams 2010). 456 
Despite reports of changes in MME protein in extra-capsular disease we saw no evidence of 457 
significant differences between localised and metastatic cohorts. It may be that without the addition of 458 
the known prostate biomarker AGR2, MME does not sufficient power alone (Bu, et al. 2011; Kani, et 459 
al. 2013).  460 
 461 
We hypothesised that some of the differences seen between the metastatic and localised cohorts were 462 
as a result of androgen regulation of the identified genes. This was investigated using published ChIP-463 
seq data which showed strong AR binding to the FAM129A and MME loci in multiple cell lines 464 
consistent with previous reports of altered regulation of FAM129A in cells treated with the anti-465 
androgen, bicalutamide (Massie et al. 2011; Rothermund, et al. 2005; Wang et al. 2009; Yu et al. 466 
2010). This also suggests that MME and FAM129A are novel androgen regulated genes and this was 467 
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confirmed by demonstrating enrichment of AR binding to the MME, FAM129A and KRT7 promoters 468 
following treatment with androgen (Figure 5C). These data suggest that FAM129A expression at the 469 
mRNA and protein level may initially increase in hormone sensitive tissue before decreasing in 470 
patients with hormone refractory disease. This is consistent with an alternatively regulated AR 471 
signalling axis and alterations in AR binding sites previously reported in advanced disease (Sharma, et 472 
al. 2013; Tsao, et al. 2012). This supports the inclusion of androgen regulated genes in a recently 473 
published 17-gene panel to predict aggressive prostate cancer (Klein et al. 2014). 474 
 475 
This study has identified a four gene panel of circulating mRNA that can distinguish metastatic from 476 
benign disease in a small patient cohort. Although there was frequent concordance between mRNA 477 
expression between circulating mRNA and tissue mRNA, there were frequently differences between 478 
expression of FAM129A, KRT7, SOD2 and MME at the mRNA and protein level in many of the 479 
cohorts. Androgen regulation of FAM129A,MME and KRT7 confirms the continuing role of the AR 480 
in advanced prostate cancer. This study demonstrates altered AR regulated gene expression during 481 
different stages of the prostate cancer disease pathway that can be detected using a minimally invasive 482 
blood test. Further work is required to determine if an AR regulated gene panel, either alone or in 483 
combination with genes identified in other PAXgene studies, could have clinical utility in predicting 484 
aggressive disease or monitoring response to hormone manipulating treatments such as bicalutamide, 485 
aberaterone and enzalutamide. 486 
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 730 
Figure legends 731 
Figure 1: Identification of differentially expressed genes in circulating mRNA. (A) A schematic 732 
overview of the study design giving numbers of patients and genes included at each stage (n). (B) A 733 
heat map of clustered results from the HT12 expression arrays for the 6 identified genes (SOD2, 734 
FAM129A, MME, KRT7, PPA1 and DPM3). Multiple probes for these genes that appeared in the top 735 
1000 most DE probes are shown. Red indicates high expression while blue indicates low expression. 736 
(C) Boxplots showing the expression array data for each probe shown in (B), where multiple probes 737 
exist for a gene all probes are shown. Limma p-values for diffential gene expression are shown. (D) 738 
qPCR validation of expression array results. Ct values were calculated for all conditions and the 739 
expression of target genes was normalised against the expression of RPLP2 housekeeping gene using 740 
the δδCt method. All primer sequences are given in Supplementary Table 5. All p-values were 741 
calculated using a Mann Whitney 2-tailed t-test. The control group in all Figures were patients with 742 
raised PSA, negative biopsy. 743 
 744 
Figure 2: Expression of FAM129A, KRT7, SOD2 and MME in tissue and serum from metastatic 745 
patients. (A) Box and whisker plots were generated from previously published data on metastatic and 746 
control cohorts (Taylor et al. 2010). P-values were calculated using a Wilcoxon rank-sum test. (B) 747 
Immunohistochemistry (IHC) for the 4 genes on biopsy tissue taken from the patients assayed in Figure 748 
1. All IHC was performed on the Bondmax Autostainer using the antibodies FAM129A (1:750), KRT7 749 
(2.8g/L), SOD2 (1:1500) and MME (1:50). Staining is shown in brown with nuclei shown in blue and 750 
was classified into the following categories: none, weak, moderate and high, based on intensity. (C) An 751 
ELISA developed on the MesoScale Discovery platform was used to determine the amount of MME 752 
protein in the serum from patients previously tested in the discovery cohort. Plates were coated with 753 
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goat anti-MME (1.44µg/ml) and MME protein detected with biotinylated goat anti-MME (1:100) before 754 
visualising using streptavidin sulphoTAG (1:1000) and measured using a Sector 6000 plate reader.  755 
Figure 3: Expression of FAM129A, KRT7, SOD2 and MME in different risk cohorts. Patients were 756 
defined as low, intermediate or high risk based on the following clinical criteria; low risk – PSA 757 
≤10ng/ml, Gleason 6, ≥T2, intermediate risk – PSA ≥10ng/ml but ≤20ng/ml, Gleason 7, ≥T2 or high 758 
risk – PSA ≥20ng/ml, Gleason ≥8, ≥T3. The clinical characteristics of the risk cohort are given in 759 
Supplementary Table 3. (A)The circulating mRNA for the 4 genes was determined in 3 risk cohorts by 760 
qPCR. Ct values were calculated for all conditions and the expression of target genes was normalised 761 
against the expression of RPLP2 housekeeping gene using the δδCt method. Kruskal Wallis tests for 762 
each gene testing the likelihood of a result falling into any group by chance gave the following results; 763 
FAM129A – p=0.34, KRT7 – p=0.0017, SOD2 – p=0.79 and MME p=0.033. All p-values were 764 
calculated using a Mann Whitney 2-tailed t-test. (B) Recursive partitioning was performed using Ct 765 
values from the qPCR validation to predict cut-offs for each group within the data. Only genes showing 766 
significant results are shown. Ct cut-off values and 95% confidence intervals are indicated. High – high 767 
risk, inter – intermediate risk, low – low risk. (C) Expression of FAM129A, KRT7, SOD2 and MME  768 
was determined in localised prostate using published expression data (Taylor et al. 2010) and p-values 769 
determined using a Wilcoxon rank-sum test (D) Alterations in the protein levels of FAM129A, KRT7, 770 
SOD2 and MME in localised disease was determined by IHC using an in-house TMA previously 771 
described where G3, G4 and G5 refer to Gleason grades (Whitaker et al. 2010; Whitaker et al. 2013). 772 
All IHC was performed on the Bondmax Autostainer using conditions described before. Staining is 773 
shown in brown with nuclei shown in blue and was classified into the following categories: none, weak, 774 
moderate and high, based on intensity. P-values were calculated using a Kruskal Wallis test. 775 
 776 
Figure 4: Hormone regulation of FAM129A, KRT7, SOD2 and MME in patient cohorts. (A) The 777 
circulating mRNA for the 4 genes was determined in 3 hormone cohorts by qPCR; patients yet to 778 
receive treatment (hormone naive), receiving hormone treatment and continuing to respond (hormonal 779 
therapy) and patients who have become hormone refractory (hormone relapsed). Ct values were 780 
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calculated for all conditions and the expression of target genes was normalised against the expression 781 
of RPLP2 housekeeping gene using the δδCt method. Kruskal Wallis tests for each gene testing the 782 
likelihood of a result falling into any group by chance gave the following results; FAM129 – 783 
p=0.0085, KRT7 – p=0.038, SOD2 – p=0.014 and MME p=0.0079. All p-values shown were 784 
calculated using a Mann Whitney 2-tailed t-test between two groups. (B) Recursive partitioning was 785 
performed using Ct values from the qPCR validation to predict cut-offs for each group within the 786 
data. Only genes showing significant results are shown. Ct cut-off values and 95% confidence 787 
intervals are indicated. HN – never received hormone treatment (hormone naïve), HT – receiving 788 
hormone treatment and responding (hormonal therapy) and HR – receiving hormone treatment and 789 
showing biochemical or clinical relapse (hormone relapsed). (C) Alterations in the protein levels of 790 
FAM129A, KRT7, SOD2 and MME with hormone status was determined by IHC using a hormone 791 
refractory TMA described in Supplementary Table 7. All IHC was performed on the Bondmax 792 
Autostainer using conditions described before. Staining is shown in brown with nuclei shown in blue 793 
and was classified into the following categories: none, weak, moderate and high, based on intensity. 794 
P-values across all groups were calculated using a Kruskal-Wallis test and pairwise comparisons 795 
using a Mann-Whitney two-tailed t-test. 796 
 797 
Figure 5: Androgen regulation of the 4 gene panel. (A) Androgen regulation of the 4 genes was 798 
determined in the LNCaP cell line by treating with androgens and taking samples for expression 799 
analysis over the following 24 hours (Massie et al. 2011). Filled circles represent androgen treatment, 800 
open circles represent vehicle controls. Data for all good probes is shown for FAM129A. Data for 801 
other genes is shown in Supplementary Figure 6. ACF = autocorrelation (function). A measure greater 802 
than zero means that consecutive time points are nearer each other than time points chosen at random. 803 
(B) UCSC genome browser view of the FAM129A and MME loci showing AR binding profiles in 804 
prostate cancer cells from three independent studies (Massie et al. 2011; Wang et al. 2009; Yu et al. 805 
2010).  Coloured blocks indicate AR peaks identified in each of the three chIP studies, red peaks show 806 
the AR chIP-seq profile for two cell lines (Massie et al. 2011).  Below gene annotations are ENCODE 807 
tracks indicating promotor, enhancer, DNAse hypersensitivity and transcription factor binding 808 
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profiles.  Arrows indicate promoters and direction of transcription. Data for KRT7 and SOD2 are 809 
shown in Supplementary Figure 7. (C) chIP for the AR in the LNCaP cell line following starvation for 810 
48 hours in charcoal stripped media and treatment with 10-8M R1881 for 1 hour (black bars). Data is 811 
shown as relative to vehicle treated cells (grey bars). P-values are calculated using a Wilcoxon rank-812 
sum test 813 
 814 
Table 1: Clinical data for the Discovery cohort and template biopsy confirmed benign cohort. 815 
N=number of patients with percentage given in in brackets afterwards. *Age and PSA data collected 816 
at time of diagnosis. 817 
 818 
Table 2: Clinical data for the defined hormone status cohort. N=number of patients with percentage 819 
given in in brackets afterwards. *Age and PSA data collected at time of diagnosis. 820 
 821 
Table 3: Clinical data for the risk stratified. N=number of patients with percentage given in in 822 
brackets afterwards. *Age and PSA data collected at time of diagnosis. The median proportion of 823 
positive cores is also given for each group with the range shown in brackets. 824 
 825 
Table 4: Clinical data for the hormone relapsed (HR) TMA generated in Cambridge. N=number of 826 
patients with percentage given in in brackets afterwards.  827 
 828 
 829 
Table 5: An overview of the data generated at the mRNA and protein level in the three different 830 
cohorts used in this study. Intermediate (inter) versus high risk (high) is shown for the risk cohort. A 831 
statistically significant decrease or increase is shown by ↓ (blue shading) and ↑ (red shading) 832 
respectively. Data that was not significant is shown as ↔ (yellow shading). 833 
 834 
Supplementary Figure 1: Quality control data of signal versus noise from the expression arrays of 835 
globin-reduced and non-reduced samples. The X-axis represents P95 (signal) values and the Y-Axis 836 
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represents P05 (noise) values. The red line represents a signal to noise ratio of 10 which is 837 
recommended by the array manufacturers (B) and (C) Expression versus variability of a set of classic 838 
housekeeping genes is shown in the globin-reduced and non-reduced expression data. The horizontal 839 
lines represent the median values of the respective distributions. RPLP2 was selected as the control 840 
gene. 841 
 842 
Supplementary Figure 2: siRNA targeting FAM129A, SOD2 and MME or a non-targeting control 843 
(NT) was used to transiently knock-down each gene in LNCaP cells for 72 hours. Half of the cells 844 
were harvested for qPCR validation of knock-down (A) while the remainder were loosely pelleted, 845 
formalin fixed for 16 hours and made into a paraffin embedded cell pellet. Sections of this pellet were 846 
stained by IHC for the respectively gene (B).  847 
 848 
Supplementary Figure 3: Haematological parameters including haemoglobin, white cell count (WCC) 849 
and platelets for patients included in the Discovery Cohort described in Supplementary Table 1. The 850 
benign cohort represents those patients with raised PSA and negative TRUS biopsy. 851 
 852 
Supplementary Figure 4: A heatmap showing the 100 differentially expressed genes in the discovery 853 
cohort as determined using the non-globin reduced samples. Differential expression analysis was 854 
carried out using the limma package and genes selected for further analysis by ranking according to 855 
Benjamini-Hochberg calculated, unadjusted, p-values and a cut off of 0.01. Blue represents down-856 
regulated genes and red overexpressed genes. 857 
 858 
Supplementary Figure 5: qPCR of circulating mRNA for FAM129A, KRT7, SOD2 and MME from 859 
two benign cohorts; raised PSA negative template biopsy and raised PSA negative TRUS biopsy. Ct 860 
values were calculated for all conditions and the expression of target genes was normalised against the 861 
expression of RPLP2 housekeeping gene using the δδCt method. P-values were calculated using a 862 




Supplementary Figure 6: Kaplan Meier curves for FAM129A, KRT7, SOD2 and MME in the Taylor 865 
et al. (Taylor et al. 2010) (A) or Glinsky et al. (Glinsky et al. 2004) (B) datasets generated using 866 
recursive partitioning. Red indicates high expression and blue indicates low expression. P-values were 867 
calculated using a Jonckheere-Terpstra test. 868 
 869 
Supplementary Figure 7: Androgen regulation of the 4 genes was determined in the LNCaP cell line 870 
by treating with androgens and taking samples for expression analysis over the following 24 hours 871 
(Massie et al. 2011). Filled circles represent androgen treatment, open circles represent vehicle 872 
controls. Data for all probes is shown. UCSC genome browser view of the FAM129A and MME loci 873 
showing AR binding profiles in prostate cancer cells from three independent studies (Massie et al. 874 
2011; Wang et al. 2009; Yu et al. 2010).  Coloured blocks indicate AR peaks identified in each of the 875 
three chIP studies, red peaks show the AR chIP-seq profile for two cell lines (Massie et al. 2011).  876 
Below gene annotations are ENCODE tracks indicating promoter, enhancer, DNAse hypersensitivity 877 
and transcription factor binding profiles.  Arrows indicate promoters and direction of transcription.  878 
 879 
Supplementary Table 1: Overview of genes identified in HT12 arrays. A brief overview of current 880 
knowledge is given under ‘function’ and any known links to any cancer and specifically prostate 881 
cancer.  882 
 883 
Supplementary Table 2: Genes to be validated in additional datasets were identified by expression 884 
array analysis of non-haemoglobin reduced samples. Differential expression analysis was carried out 885 
using the limma package and genes selected for further analysis by ranking according to Benjamini-886 
Hochberg calculated, unadjusted, p-values and a cut off of 0.01. Genes with a significant association 887 
with poor outcome in either Taylor or Glinsky dataset are highlighted in red. Preference was given to 888 
genes with good antibody availability. Antibodies were ranked by HW according to published 889 
staining examples in prostate cancer; 5* - strong, crisp staining, no background, demonstrates clear 890 
ability to discriminate between benign and tumour cells, 4* - strong staining, low non-specific binding 891 
or limited ability to discriminate between benign and tumour cells, 3* - moderate staining with 892 
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moderate non-specific staining, 2* - weak or moderate staining with high levels of non-specific 893 
staining, 1* - no or weak staining seen, N/a  - no antibody staining pictures available for assessment. 894 
Genes taken forward in this study are highlighted in yellow. 895 
 896 
Supplementary Table 3: Primers used for qPCR validation of genes identified in the expression array. 897 
All sequences are shown 5’to 3’.  898 
 899 
Supplementary Table 4: Primers used for chIP experiment. All sequences are shown 5’to 3’.  900 






Expression array and candidate gene 
identification 
(6 genes)
Validated gene signature 
(4 genes + PSA)
Localised cancer cohort 
(low - 12, intermediate - 21 , high – 14) 
Hormone sensitivity cancer cohort
(hormone naïve - 9, stable disease - 12, 
hormone refractory – 12)
Discovery cohort























































































































































Benign G3 G4 G5
Figure 3Thomas et al.
A









































































































































































93 n= 479 15 104


















































Thomas et al. Supplementary Figure 1















































Supplementary Figure 3Thomas et al.
Haemoglobin PlateletsWhite cell count
p=0.83p=0.09 p=0.44
n= 910 n= 910 n= 910
Supplementary Figure 4Thomas et al.








Supplementary Figure 6Thomas et al.
A
B
 Supplementary Figure 7Thomas et al.
A
B







Median age in years* 
(range) 65.0 (54.0-83.0) 66.5 (52.0-80.0) 61.0 (50.0-67.0) 
Median PSA* (range) 43.0 (3.9-609.0)  7.7 (4.2-18.6) 10.8 (3.8-15.5) 
Gleason sum score    
6 (%) 0/10 (0%)   
7 (%) 1/10 (20%) N/A N/A 
≥8 (%) 9/10 (90%) N/A N/A 
Clinical stage    
T3  7/10 (70%) N/A N/A 
T4  3/10 (30%) N/A N/A 
Hormone status    
Hormone naïve 6/10 (60%) N/A N/A 
On hormone therapy 4/10 (40%) N/A N/A 




Table 2: Risk stratified validation cohort 






Median age in years* 
(range) 61.0 (51.0-71.0) 66.0 (53.0-87.0) 69.0 (55.0-79.0) 
Median PSA* (range) 5.7 (2.7-10.0) 9.0 (2.1-18.5) 14.0 (4.0-149.0) 
Gleason score    
6 (%) 12/12 (100%) 0/21 (0%) 1/14 (7%) 
7 (%) 0/12 (0%) 21/21 (100%) 1/14 (7%) 
≥8 (%) 0/12 (0%) 0/21 (0%) 12/14 (86%) 
Clinical stage    
T2 12/12 (100%) 19/21 (91%) 7/14 (50%) 
T3  0/12 (0%) 2/21 (9%) 7/14 (50%) 
T4 0/12 (0%) 0/21 (0%) 0/14 (0%) 
+ve biopsy cores (%) 21% (6%-67%) 31% (8%-73%) 78% (17%-100%) 
 
 
Table 3: Defined hormone status validation cohort 







Median age in years* 
(range) 75.0 (64.0-93.0) 66.5 (61.0-88.0) 71.0 (51.0-82.0) 
Median PSA* (range) 123.0 (12.5-511.6) 85.0 (7.4-6470.0) 41.1 (2.0-405.0) 
Gleason sum score    
No biopsy taken, 
diagnosis based on 
clinical criteria 
3/9 (33%) 6/12 (50%) 4/12 (34%) 
6 0/10 (0%) 1/12 (8%) 1/12 (8%) 
7 1/10 (11%) 3/12 (25%) 1/12 (8%) 
≥8 5/10 (56%) 2/12 (17%) 6/12 (50%) 
Clinical stage    
T2 0/9 (0%) 1/12 (8%) 1/12 (8%) 
T3  7/9 (77%) 9/12 (75%) 8/12 (67%) 




Table 4: Hormone relapse TMA 
Treatment Number of patients (%) 




Relapse on LHRH 19 (32.2%) 
Relapse on complete 
androgen blockade 18 (30.5%) 
Relapse following 
external beam radiation 9 (15.2%) 
Salvage TURP post 













(HN vs HR) 























FAM129A ↓/↓ ↓ ↔ ↓ ↔ ↔ ↔ ↑ 
KRT7 ↓/↔ ↓ ↓ ↓ ↓ ↓ ↓ ↓ 
SOD2 ↓/↓ ↓ ↔ ↔ ↑ ↔ ↑ ↓ 
MME ↓/↓ ↓ ↓ ↔ ↑ ↓ ↓ ↓ 
Supplementary Table 1: 
Gene 
name Aliases Function Role in any cancer 














cancers of head 
and neck, thyroid, 
renal.  
None (Adachi, et al. 
2004; Cerutti, 
et al. 2006; 
Ito, et al. 
2010; Ji, et al. 
2012; 
Matsumoto, 
et al. 2006; 
Patel, et al. 
2011; Sun, et 
al. 2007) 












gastric and ovarian 
cancers. 
None (Jeong, et al. 
2012; 
Megger, et al. 
2013; Wang, 
et al. 2012) 












(Ashida, et al. 
2006; Manos, 

































Giesing, et al. 
2012; 












Used in many 
cancer types as a 











et al. 2001) 



















et al. 2008; 
Ho, et al. 
2013; 
Maguer-
Satta, et al. 
2011; 
Voutsadakis, 
et al. 2012) 
  
IlluminaID SYMBOL logFC t P.Value adj.P.Val B Taylor/Sawyers significant Glinsky significant Ab quality Ab source/IComments
ILMN_1667966 FAM129A 7.05E-01 5.42E+00 9.15E-06 0.2297948 2.56199472 5.20E-04 0.047 **** HPA Strong staining
ILMN_2405667 CLDN15 -2.58E-01 -5.41E+00 9.55E-06 0.2297948 2.53127346 1.50E-02 0.0057 *** HPA Moderate staining, no discrimination betw een tumour/normal
ILMN_2163723 KRT7 2.43E-01 5.18E+00 1.78E-05 0.284781 2.08562967 1.50E-01 0.04 ***** HPA/ Strong staining
Novocastra
ILMN_1777344 RPS13 -4.53E-01 -4.89E+00 3.85E-05 0.3512191 1.52292897 8.50E-01 NA * HPA No expression
ILMN_1660063 POLE4 -4.21E-01 -4.74E+00 5.82E-05 0.3512191 1.22062321 4.70E-01 NA N/A HPA None available
ILMN_2402674 DPM3 -3.90E-01 -4.74E+00 5.88E-05 0.3512191 1.21376562 2.30E-02 0.62 **** HPA Strong staining
ILMN_2117330 NDUFB2 -4.11E-01 -4.69E+00 6.62E-05 0.3512191 1.12636348 7.50E-01 0.46 * HPA Very w eak
ILMN_1657862 AHCY -3.29E-01 -4.62E+00 8.11E-05 0.3512191 0.97703084 6.80E-02 0.32 * HPA Weak and non-specif ic staining
ILMN_1745946 HAUS1 -2.25E-01 -4.60E+00 8.55E-05 0.3512191 0.93735357 1.20E-01 NA ** HPA Moderate staining, lots of non-specif ic staining in muscle
ILMN_1701603 ALPL 7.61E-01 4.50E+00 1.10E-04 0.3512191 0.74858287 1.20E-01 0.16 ** HPA Weak/moderate staining
ILMN_2347068 MKNK2 4.20E-01 4.50E+00 1.11E-04 0.3512191 0.74698355 2.60E-01 0.97 ** HPA Weak/moderate staining
ILMN_1654778 LSP1 3.73E-01 4.47E+00 1.21E-04 0.3512191 0.67959336 1.00E-01 0.059 * HPA No epithelial expression
ILMN_1726603 ATP5I -3.33E-01 -4.43E+00 1.35E-04 0.3512191 0.60067172 5.40E-01 0.21 ***** HPA Strong staining
ILMN_1805827 PPA1 -5.49E-01 -4.37E+00 1.60E-04 0.3609522 0.47498633 8.90E-01 0.022 **** HPA Moderate staining, excellent discrimination benign/cancer
ILMN_3241091 TMEM164 6.66E-01 4.36E+00 1.62E-04 0.3609522 0.46532921 3.80E-01 0.13 ** HPA Weak, lots of non-specif ic
ILMN_1678814 UBL5 -2.93E-01 -4.33E+00 1.75E-04 0.3609522 0.40800261 9.20E-01 0.00005 N/A HPA None available
ILMN_1749432 MRPL32 -2.86E-01 -4.30E+00 1.94E-04 0.3609522 0.33075996 1.10E-01 NA * HPA No/w eak staining
ILMN_1709880 RPLP0 -5.10E-01 -4.25E+00 2.19E-04 0.3609522 0.2412398 1.50E-01 0.29 ** HPA Weak/moderate staining
ILMN_1786920 KDM5A 3.43E-01 4.22E+00 2.36E-04 0.3609522 0.18506283 1.70E-02 0.11 *** HPA Moderate staining, no discrimination betw een tumour/normal
ILMN_1701875 ZYX 4.21E-01 4.21E+00 2.46E-04 0.3609522 0.15170055 3.20E-01 0.0078 * HPA Very w eak
ILMN_1669177 DHRS12 2.29E-01 4.20E+00 2.50E-04 0.3609522 0.13987586 3.50E-01 0.053 ** HPA Weak/moderate staining
ILMN_2227573 GSTO1 -3.14E-01 -4.20E+00 2.52E-04 0.3609522 0.13442907 9.10E-01 0.38 * HPA No/w eak staining
ILMN_1693274 USHBP1 2.08E-01 4.19E+00 2.57E-04 0.3609522 0.12001158 1.50E-01 NA ** HPA Weak/moderate staining
ILMN_2406501 SOD2 6.79E-01 4.17E+00 2.74E-04 0.3609522 0.07258804 6.10E-05 NA ***** HPA Strong staining, some discrimination
ILMN_2400360 PRSS54 2.55E-01 4.16E+00 2.81E-04 0.3609522 0.05338254 5.70E-02 NA *** HPA Moderate staining, possible discrimination betw een tumour/normal
ILMN_1793729 C15orf39 4.30E-01 4.14E+00 2.92E-04 0.3609522 0.02520559 NA NA * HPA No/w eak staining
ILMN_3239426 GPN3 -2.94E-01 -4.14E+00 2.92E-04 0.3609522 0.02476414 9.20E-01 0.81 * HPA No/w eak staining
ILMN_1714623 TOMM22 -2.88E-01 -4.12E+00 3.07E-04 0.3609522 -0.01373511 2.70E-01 0.11 ***** HPA Strong staining
ILMN_1766275 PIK3CD 2.52E-01 4.12E+00 3.15E-04 0.3609522 -0.03236825 4.60E-02 0.14 * HPA No/w eak staining
ILMN_1746408 MIDN 3.76E-01 4.10E+00 3.29E-04 0.3609522 -0.06343384 2.80E-01 NA * HPA No/w eak staining
ILMN_1789692 MARK2 2.20E-01 4.09E+00 3.35E-04 0.3609522 -0.07715236 4.60E-01 0.039 *** HPA Moderate staining
ILMN_1728885 KIAA1644 2.15E-01 4.09E+00 3.41E-04 0.3609522 -0.09024041 4.50E-01 0.058 *** HPA Moderate staining
ILMN_1651826 BASP1 5.03E-01 4.07E+00 3.56E-04 0.3609522 -0.12301803 7.50E-01 0.053 ***** HPA Strong staining, some discrimination
ILMN_2169025 JOSD2 -2.51E-01 -4.06E+00 3.64E-04 0.3609522 -0.14096234 1.20E-01 NA N/A HPA None available
ILMN_2146761 FABP5 -2.83E-01 -4.03E+00 3.99E-04 0.3609522 -0.20925884 9.40E-01 0.82 **** HPA Strong staining in a small proportion of cancers, others negative
ILMN_1725534 ACTN4 3.26E-01 4.03E+00 4.00E-04 0.3609522 -0.21099725 6.10E-02 0.19 ***** HPA Strong staining
ILMN_1746704 TRIM8 2.73E-01 4.02E+00 4.01E-04 0.3609522 -0.21309143 9.90E-01 0.14 * HPA No/w eak staining
ILMN_3246658 USP18 -4.43E-01 -4.02E+00 4.02E-04 0.3609522 -0.2151573 9.00E-01 0.63 * HPA No/w eak staining, strong staining in muscle
ILMN_1680397 CXCR2 6.18E-01 4.01E+00 4.14E-04 0.3609522 -0.2364445 3.50E-02 0.66 * HPA No/w eak staining
ILMN_1738207 CISH -2.62E-01 -4.01E+00 4.17E-04 0.3609522 -0.24219118 8.00E-01 0.019 *** HPA Moderate staining
ILMN_1688864 CABP4 2.44E-01 4.01E+00 4.18E-04 0.3609522 -0.24362427 1.80E-01 NA * HPA No/w eak staining
ILMN_2072603 MRPL14 -2.60E-01 -3.99E+00 4.43E-04 0.3609522 -0.28759452 5.60E-04 NA *** HPA Moderate staining, possible discrimination betw een tumour/normal
ILMN_1810420 DYSF 5.90E-01 3.98E+00 4.49E-04 0.3609522 -0.29798572 7.80E-02 0.75 * HPA No/w eak staining
ILMN_1698940 RPL15 -3.49E-01 -3.98E+00 4.52E-04 0.3609522 -0.30157664 1.70E-01 0.0058 * HPA No/w eak staining
ILMN_1716060 ERC1 2.41E-01 3.98E+00 4.56E-04 0.3609522 -0.30839306 7.50E-04 0.034 *** HPA Moderate/strong staining, various localisations
ILMN_1764500 BRK1 -2.40E-01 -3.97E+00 4.60E-04 0.3609522 -0.31617082 1.00E-01 NA N/A HPA None available
ILMN_1705419 C1orf213 -2.01E-01 -3.97E+00 4.65E-04 0.3609522 -0.32349844 NA NA * HPA No/w eak staining
ILMN_2375418 DPH2 -2.07E-01 -3.97E+00 4.69E-04 0.3609522 -0.32927813 2.20E-02 0.1 * HPA No/w eak staining
 IlluminaID SYMBOL logFC t P.Value adj.P.Val B Taylor/Sawyers significant Glinsky significant Ab quality Ab source/IComments
ILMN_1655377 MRPS22 -2.83E-01 -3.95E+00 4.90E-04 0.3609522 -0.36360326 2.90E-01 0.75 *** HPA Moderate staining
ILMN_3215743 LOC646808 -2.11E-01 -3.95E+00 4.91E-04 0.3609522 -0.36512181 NA NA N/A HPA None available
ILMN_2228710 PDCD5 -3.36E-01 -3.95E+00 4.94E-04 0.3609522 -0.36874949 8.80E-02 0.54 ***** HPA Strong staining, some discrimination
ILMN_3252750 LOC100129033 -1.88E-01 -3.95E+00 4.94E-04 0.3609522 -0.3692881 NA NA N/A HPA None available
ILMN_1706326 MRPL33 -3.38E-01 -3.95E+00 4.95E-04 0.3609522 -0.37087403 4.50E-01 0.99 N/A HPA None available
ILMN_3268697 RPL31 -4.00E-01 -3.93E+00 5.17E-04 0.3662037 -0.40350473 2.90E-01 0.025 N/A HPA None available
ILMN_3191263 ZNF496 2.44E-01 3.91E+00 5.44E-04 0.3665536 -0.44128924 1.10E-01 NA * HPA No/w eak staining
ILMN_1801710 APBB1IP 3.93E-01 3.91E+00 5.49E-04 0.3665536 -0.44765023 5.90E-01 0.53 * HPA No/w eak staining
ILMN_1651692 STK10 2.72E-01 3.91E+00 5.50E-04 0.3665536 -0.44913407 1.90E-01 0.69 * HPA No/w eak staining
ILMN_1777906 MAP7D1 3.24E-01 3.90E+00 5.56E-04 0.3665536 -0.45815583 4.70E-01 0.0004 * HPA No/w eak staining
ILMN_1732575 SEC14L1 4.28E-01 3.89E+00 5.70E-04 0.3692906 -0.47668911 6.30E-01 0.057 ***** HPA Strong staining
ILMN_1710514 BCL3 4.01E-01 3.89E+00 5.76E-04 0.3692906 -0.48405835 7.60E-02 0.033 ** HPA Weak/moderate staining
ILMN_1721344 MOBKL2A 3.66E-01 3.87E+00 5.99E-04 0.3790569 -0.5136351 NA NA * HPA No/w eak staining
ILMN_1800993 CLUAP1 -2.22E-01 -3.86E+00 6.14E-04 0.3836048 -0.53242992 2.00E-01 0.09 *** HPA Moderate/strong staining, no discrimination
ILMN_2396648 EXOSC1 -2.55E-01 -3.84E+00 6.52E-04 0.3892703 -0.57784993 2.90E-02 0.3 *** HPA Moderate staining
ILMN_1722620 MGC39584 1.78E-01 3.84E+00 6.64E-04 0.3892703 -0.59082668 NA NA N/A HPA None available
ILMN_1683660 EIF3H -2.64E-01 -3.84E+00 6.64E-04 0.3892703 -0.59108285 2.20E-01 0.33 *** HPA Moderate staining, possible discrimination betw een tumour/normal
ILMN_3225894 FAM207A -2.70E-01 -3.83E+00 6.74E-04 0.3892703 -0.60285284 8.90E-03 NA ***** HPA Strong staining, no discrimination
ILMN_1790757 ADSL -2.41E-01 -3.82E+00 6.85E-04 0.3892703 -0.61459751 3.00E-01 0.043 *** HPA Moderate/strong staining, no discrimination
ILMN_1678966 SNRPF -3.33E-01 -3.82E+00 6.86E-04 0.3892703 -0.61578841 1.50E-01 0.068 N/A HPA None available
ILMN_1815054 GPR97 4.01E-01 3.82E+00 6.91E-04 0.3892703 -0.62119907 3.00E-02 0.58 *** HPA Moderate staining
ILMN_1665909 LASP1 2.96E-01 3.80E+00 7.38E-04 0.3892703 -0.671272 8.60E-01 0.12 *** HPA Moderate staining
ILMN_1700477 MRPL43 -2.21E-01 -3.79E+00 7.43E-04 0.3892703 -0.67569775 6.20E-01 NA N/A HPA None available
ILMN_1811991 C17orf101 1.98E-01 3.79E+00 7.45E-04 0.3892703 -0.6774734 NA NA * HPA No/w eak staining
ILMN_1771987 SLC44A2 2.68E-01 3.79E+00 7.48E-04 0.3892703 -0.68142212 3.50E-01 NA * HPA No/w eak staining
ILMN_1690371 MRPL11 -2.43E-01 -3.79E+00 7.51E-04 0.3892703 -0.68371705 1.70E-02 0.59 *** HPA Weak/moderate staining, possible discrimination betw een tumour/normal
ILMN_1677827 TLR7 -3.38E-01 -3.79E+00 7.52E-04 0.3892703 -0.68544161 9.70E-03 0.48 * HPA No/w eak staining
ILMN_2393169 THOC5 2.71E-01 3.79E+00 7.54E-04 0.3892703 -0.68696011 4.10E-01 0.21 * HPA No/w eak staining
ILMN_1800197 MRPL36 -2.61E-01 -3.78E+00 7.62E-04 0.3892703 -0.69538763 1.70E-01 NA *** HPA Moderate staining, possible discrimination betw een tumour/normal
ILMN_1742450 TAPBP 3.54E-01 3.76E+00 8.02E-04 0.3892703 -0.73366022 1.50E-01 0.58 *** HPA Moderate staining
ILMN_1662524 CXCR1 5.68E-01 3.76E+00 8.15E-04 0.3892703 -0.74520579 1.70E-02 0.43 * HPA No/w eak staining
ILMN_1774584 C2orf28 -2.59E-01 -3.75E+00 8.21E-04 0.3892703 -0.75152148 NA NA * HPA No/w eak staining
ILMN_1787026 SEC61G -3.74E-01 -3.75E+00 8.40E-04 0.3892703 -0.76854983 3.80E-01 0.018 * HPA No/w eak staining
ILMN_2067370 SNRPF -3.89E-01 -3.73E+00 8.69E-04 0.3892703 -0.7942236 1.50E-01 6.80E-02 N/A HPA None available
ILMN_1753912 ABHD11 1.98E-01 3.73E+00 8.73E-04 0.3892703 -0.79751531 8.10E-03 0.28 *** HPA Moderate staining, possible discrimination betw een tumour/normal
ILMN_3307772 PACSIN2 3.37E-01 3.73E+00 8.86E-04 0.3892703 -0.80875555 8.00E-03 0.64 *** HPA Moderate/strong staining
ILMN_1660847 PFKFB3 2.80E-01 3.72E+00 9.06E-04 0.3892703 -0.8254048 2.00E-02 0.53 *** HPA/SDIX Moderate staining
ILMN_2262362 ABCG1 2.61E-01 3.72E+00 9.10E-04 0.3892703 -0.82819301 8.90E-01 1.60E-01 * HPA No/w eak staining
ILMN_1692707 PTRHD1 -2.17E-01 -3.71E+00 9.16E-04 0.3892703 -0.83370526 4.00E-01 NA ** HPA Weak/moderate staining
ILMN_2100815 TMEM9B -2.20E-01 -3.71E+00 9.34E-04 0.3892703 -0.84824095 2.70E-01 4.40E-01 *** HPA Moderate staining, lots of non-specif ic staining 
ILMN_1696554 UBE2Q2P1 -1.81E-01 -3.71E+00 9.36E-04 0.3892703 -0.85007213 1.40E-01 NA N/A HPA None available
ILMN_3290681 OGFOD1 2.18E-01 3.70E+00 9.38E-04 0.3892703 -0.85143553 1.00E-01 8.60E-01 ** HPA Weak/moderate staining
ILMN_2391765 C6orf48 -5.03E-01 -3.70E+00 9.39E-04 0.3892703 -0.85243815 NA NA N/A HPA None available
ILMN_1669033 NCOA1 3.60E-01 3.70E+00 9.45E-04 0.3892703 -0.85717582 7.00E-01 1.60E-01 **** HPA/ Moderate/strong staining, possible discrimination betw een tumour/normal
Cell signalling Technology
ILMN_1739497 GTF2H5 -2.03E-01 -3.70E+00 9.52E-04 0.3892703 -0.86239138 1.10E-01 3.00E-01 *** HPA/ Moderate staining
Sigma Aldrich
ILMN_2275396 ADORA1 -1.96E-01 -3.70E+00 9.54E-04 0.3892703 -0.86424815 2.40E-02 7.00E-01 N/A HPA None available
ILMN_2206716 JTB -2.01E-01 -3.69E+00 9.83E-04 0.3892703 -0.88660582 1.20E-01 3.00E-01 ** HPA Weak/moderate staining
ILMN_1789793 NUAK2 2.64E-01 3.68E+00 9.91E-04 0.3892703 -0.89283829 6.40E-01 NA *** HPA Moderate staining
ILMN_2400183 DPH5 -2.23E-01 -3.68E+00 1.01E-03 0.3892703 -0.90715757 2.30E-01 1.50E-01 ** HPA Weak/moderate staining
ILMN_3235113 TOMM6 -3.08E-01 -3.67E+00 1.02E-03 0.3892703 -0.91200447 NA NA *** HPA Moderate staining
ILMN_3267017 RPLP1 -4.24E-01 -3.67E+00 1.02E-03 0.3892703 -0.9122183 1.60E-01 1.90E-01 * HPA No/w eak staining
Supplementary Table 3. 
Gene Direction of 
Primer Sequence (5’-3’) 
RPLP2 Forward AAGAAGATCTTGGACAGCGTGGGT 
Reverse TACCCTGGGCAATGACGTCTTCAA 
FAM129A Forward CCTTTCTTTGCTCAATGCAGGGCT 
Reverse AGGGCACTGATGTTCATCCATCCA 
PPA1 Forward ATCTGGAACTATGGTGCCATCCCT 
Reverse TTGGGTCATTGTCACCACAACAGC 
DPM3 Forward CTTCGGTTGAGTTTGGTCCGCTTT 
Reverse CCAAAGCCACTGCGCTAATTTCGT 
SOD2 Forward AGATAGCTCTTCAGCCTGCACTGA 
Reverse CACGTTTGATGGCTTCCAGCAACT 
KRT7 Forward TGTGGTGCTGAAGAAGGATGTGGA 
Reverse TGTCAACTCCGTCTCATTGAGGGT 
MME Forward AACAGCAACTTGGAGACGTTGTGC 
Reverse CTCCAGCAAATGCTGCTTCCACAT 
Supplementary Table 4. 
Gene Direction of 
Primer Sequence (5’-3’) 
FAM129A Forward AGAAGGGAGCAAGGGCAAAT 
Reverse AAAGGGCTCTGCTGGAAGTG 
KRT7 Forward AGGAGGGCAGTGAGATTCCT 
Reverse GTATCGGCTGTGGAGCATGT 
SOD2 Forward TCTTTCCTGCGCTGTCTTGT 
Reverse CCGCCAATGGCAGTGTAGAT 
MME Forward ACCAAGTCTTACTGTCTAATTTTGC 
Reverse TGACAGGTCTCAGTCACAACC 
Chromosome 
12B 
Forward AAAAAGCCAGGCACAGAAAA 
Reverse AACCCCCAGCTTCTGGTAAT 
